CurveBeam AI Announces Q4 Results and Investor Webinar

An update from Curvebeam AI Ltd. ( (AU:CVB) ) is now available.

CurveBeam AI Limited has announced the release of its Appendix 4C for the period ending June 30, 2025, which will be available before the market opens on July 30, 2025. The company will also host an investor webinar on the same day, led by key executives, to discuss the results. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning in the medical imaging industry.

The most recent analyst rating on (AU:CVB) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.

More about Curvebeam AI Ltd.

CurveBeam AI Limited is a company that develops, manufactures, and sells specialized medical imaging (CT) scanners, along with AI SaaS-based clinical assessment solutions. These products are designed to aid medical practitioners in managing musculoskeletal conditions. The company’s flagship product, the HiRise™ CT scanner, offers both weight-bearing and traditional non-weight-bearing CT scans, providing significant advantages over traditional CT or MRI devices. CurveBeam AI operates with over 70 employees, with its corporate office and AI functions based in Melbourne, Australia, and its global operations headquarters in Hatfield, Pennsylvania, USA.

Average Trading Volume: 182,184

Technical Sentiment Signal: Sell

Current Market Cap: A$31.61M

See more data about CVB stock on TipRanks’ Stock Analysis page.